Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). I...
Saved in:
Main Authors: | Avi Levin, Oren Shibolet |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/d7d25d975b084e1b95110d58fe7dcd89 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pediatric ulcerative colitis: current treatment approaches including role of infliximab
by: Bradley GM, et al.
Published: (2012) -
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
by: Viscido A, et al.
Published: (2019) -
Golimumab in unresponsive ulcerative colitis
by: Lippert E, et al.
Published: (2014) -
New and emerging treatments for ulcerative colitis: a focus on vedolizumab
by: Gledhill T, et al.
Published: (2013) -
Infliximab for the treatment of plaque psoriasis
by: Jennifer S Gall, et al.
Published: (2008)